Literature DB >> 22690079

Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma.

Cui-Xia Qiao1, Xiao-Feng Zhai, Chang-Quan Ling, Qing-Bo Lang, Hui-Juan Dong, Qun Liu, Mou-Duo Li.   

Abstract

AIM: To investigate and evaluate the change in health-related quality of life (HRQoL) by tumor node metastasis (TNM) staging system in patients with hepatocellular carcinoma (HCC).
METHODS: A total of 140 patients diagnosed with HCC between June 2008 and April 2009 in our department were enrolled to this study. One hundred and thirty-five (96.5%) patients had liver cirrhosis secondary to hepatitis B virus (HBV) infection, 73 (54.07%) of them being HBV DNA positive; the other etiologies of liver cirrhosis were alcoholic liver disease (1.4%), hepatitis C (1.4%) or cryptogenic (0.7%). All subjects were fully aware of their diagnosis and provided informed consent. HRQoL was assessed before treatment using the functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire. Descriptive statistics were used to evaluate demographics and disease-specific characteristics of the patients. One-way analysis of variance and independent samples t tests were used to compare the overall FACT-Hep scores and clinically distinct TNM stages. Scores for all FACT-Hep items were analyzed by frequency analyses. The mean scores obtained from the FACT-Hep in different Child-Pugh classes were also evaluated.
RESULTS: The mean FACT-Hep scores were reduced significantly from TNM Stage I to Stage II, Stage IIIA, Stage IIIB group (687 ± 39.69 vs 547 ± 42.57 vs 387 ± 51.24 vs 177 ± 71.44, P = 0.001). Regarding the physical and emotional well-being subscales, scores decreased gradually from Stage I to Stage IIIB (P = 0.002 vs Stage I; P = 0.032 vs Stage II; P = 0.033 vs Stage IIIA). Mean FACT-Hep scores varied by Child-Pugh class, especially in the subscales of physical well-being, functional well-being and the hepatobiliary cancer (P = 0.001 vs Stage I; P = 0.036 vs Stage II; P = 0.032 vs Stage IIIA). For the social and family well-being subscale, only Stage IIIB scores were significantly lower as compared with Stage I scores (P = 0.035). For the subscales of functional well-being and hepatobiliary cancer, there were significant differences for Stages IIΙ, IIIA and IIIB (P = 0.002 vs Stage I).
CONCLUSION: HRQoL of patients with HCC worsens gradually with progression of TNM stages. The most impaired subscales of HRQoL, as measured by FACT-Hep, were physical and emotional well-being.

Entities:  

Keywords:  Cross-sectional study; Functional assessment of cancer therapy-hepatobiliary; Health-related quality of life; Hepatocellular carcinoma; Tumor node metastasis staging

Mesh:

Year:  2012        PMID: 22690079      PMCID: PMC3370007          DOI: 10.3748/wjg.v18.i21.2689

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire.

Authors:  Nancy Heffernan; David Cella; Kimberly Webster; Linda Odom; Mary Martone; Steven Passik; Marilyn Bookbinder; Yuman Fong; William Jarnagin; Leslie Blumgart
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

2.  A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma.

Authors:  R T Poon; S T Fan; W C Yu; B K Lam; F Y Chan; J Wong
Journal:  Arch Surg       Date:  2001-06

3.  A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis.

Authors:  Lorenzo Montali; Atsushi Tanaka; Paolo Riva; Hiroki Takahashi; Claudio Cocchi; Yoshiyuki Ueno; Massimo Miglioretti; Hajime Takikawa; Luca Vecchio; Alessandra Frigerio; Ilaria Bianchi; Roberta Jorgensen; Keith D Lindor; Mauro Podda; Pietro Invernizzi
Journal:  Dig Liver Dis       Date:  2010-02-16       Impact factor: 4.088

Review 4.  Current treatment for hepatocellular carcinoma.

Authors:  Bridget A Cahill; Deborah Braccia
Journal:  Clin J Oncol Nurs       Date:  2004-08       Impact factor: 1.027

Review 5.  Diagnosis and treatment of hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Jorge A Marrero; Lenhard Rudolph; K Rajender Reddy
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 6.  Hepatocellular carcinoma: current management and recent advances.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-06

Review 7.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere).

Authors:  Jennifer Steel; Andrew Baum; Brian Carr
Journal:  Psychooncology       Date:  2004-02       Impact factor: 3.894

9.  Symptom concerns and quality of life in hepatobiliary cancers.

Authors:  Virginia Sun; Betty Ferrell; Gloria Juarez; Lawrence D Wagman; Yun Yen; Vincent Chung
Journal:  Oncol Nurs Forum       Date:  2008-05       Impact factor: 2.172

10.  Chemoembolization of hepatocellular carcinoma: results of a metaanalysis.

Authors:  Jean-Francois H Geschwind; Douglas E Ramsey; Michael A Choti; Paul J Thuluvath; Michael S Huncharek
Journal:  Am J Clin Oncol       Date:  2003-08       Impact factor: 2.339

View more
  13 in total

1.  Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Authors:  Masayoshi Yada; Akihide Masumoto; Kenta Motomura; Hirotaka Tajiri; Yusuke Morita; Hideo Suzuki; Takeshi Senju; Toshimasa Koyanagi
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.

Authors:  Wei-Chu Chie; Fang Yu; Mengqian Li; Lorena Baccaglini; Jane M Blazeby; Chin-Fu Hsiao; Herng-Chia Chiu; Ronnie T Poon; Naoko Mikoshiba; Gillian Al-Kadhimi; Nigel Heaton; Jozer Calara; Peter Collins; Katharine Caddick; Anna Costantini; Valerie Vilgrain; Chieh Chiang
Journal:  Qual Life Res       Date:  2015-05-06       Impact factor: 4.147

3.  Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study.

Authors:  Meng Zhang; Yaoguang Li; Zihao Fan; Dongqi Shen; Xueying Huang; Qi Yu; Mei Liu; Feng Ren; Xiao Wang; Liping Dai; Peng Wang; Hua Ye; Jianxiang Shi; Xiaoang Yang; Shunxiang Zhang; Jianying Zhang
Journal:  BMJ Open       Date:  2021-09-15       Impact factor: 3.006

Review 4.  A closer look at quality of life in the hepatocellular carcinoma literature.

Authors:  Jenny L Firkins; Robin Tarter; Martha Driessnack; Lissi Hansen
Journal:  Qual Life Res       Date:  2021-02-24       Impact factor: 4.147

Review 5.  Quality of life and hepatocellular carcinoma.

Authors:  Shipra Gandhi; Sapna Khubchandani; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2014-08

6.  Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.

Authors:  K J Hartrumpf; S Marquardt; T Werncke; T Murray; M M Kirstein; A Vogel; F Wacker; T Rodt
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

Review 7.  Value of quality of life analysis in liver cancer: A clinician's perspective.

Authors:  Leung Li; Winnie Yeo
Journal:  World J Hepatol       Date:  2017-07-18

8.  Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone.

Authors:  Taha M Hassanin; Yasser Fouad; Alshymaa Hassnine; Mohamad Eisawy; Naglaa Farag; Wael Abdel Ghany
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

9.  Quality of life analysis after stereotactic radiofrequency ablation of liver tumors.

Authors:  Peter Schullian; Anja Gertl; Gregor Laimer; Daniel Putzer; Uwe Siebert; Elliot Levy; Reto Bale
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

Review 10.  Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018.

Authors:  Danbee Kang; Sungkeun Shim; Juhee Cho; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2020-06       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.